APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripheral Vasodilator Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peripheral Vasodilator Drugs Market Outlook and Growth Opportunities 2026

23 December 2025200 pages

Choose your research edition.

Industry ResearchPeripheral Vasodilator Drugs Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripheral Vasodilator Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peripheral Vasodilator Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripheral Vasodilator Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripheral Vasodilator Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Peripheral Vasodilator Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peripheral Vasodilator Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peripheral Vasodilator Drugs market include Endovastec, Aotecar Medical-B, Tibet Cheezheng Tibetan Medicine Co., Ltd, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Pfizer, Inc., GSK plc and Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peripheral Vasodilator Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peripheral Vasodilator Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peripheral Vasodilator Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peripheral Vasodilator Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Peripheral Vasodilator Drugs Segment by Company

Endovastec

Aotecar Medical-B

Tibet Cheezheng Tibetan Medicine Co., Ltd

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis AG

Pfizer, Inc.

GSK plc

Bayer AG

Bat Medical

AstraZeneca

Viatris, Inc.

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Lupin

Bristol-Myers Squibb Company

Boehringer Ingelheim International GmbH

Abbott Laboratories

Peripheral Vasodilator Drugs Segment by Type

Alpha-adrenergic Blockers

Calcium Channel Blockers

Potassium Channel Activators

Others

Peripheral Vasodilator Drugs Segment by Application

Hospital

Retail Pharmacies

Others

Peripheral Vasodilator Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peripheral Vasodilator Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peripheral Vasodilator Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peripheral Vasodilator Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Peripheral Vasodilator Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripheral Vasodilator Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripheral Vasodilator Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripheral Vasodilator Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peripheral Vasodilator Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peripheral Vasodilator Drugs industry.

Chapter 3: Detailed analysis of Peripheral Vasodilator Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peripheral Vasodilator Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peripheral Vasodilator Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peripheral Vasodilator Drugs Industry Trends Table 2. Peripheral Vasodilator Drugs Industry Drivers Table 3. Peripheral Vasodilator Drugs Industry Opportunities and Challenges Table 4. Peripheral Vasodilator Drugs Industry Restraints Table 5. Global Peripheral Vasodilator Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peripheral Vasodilator Drugs Revenue Share by Company (2021-2026) Table 7. Global Peripheral Vasodilator Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Peripheral Vasodilator Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Peripheral Vasodilator Drugs Average Price (USD/unit) of Company (2021-2026) Table 10. Global Peripheral Vasodilator Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peripheral Vasodilator Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Peripheral Vasodilator Drugs Company, Product Type & Application Table 13. Global Peripheral Vasodilator Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peripheral Vasodilator Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alpha-adrenergic Blockers Table 18. Significant Companies of Calcium Channel Blockers Table 19. Significant Companies of Potassium Channel Activators Table 20. Significant Companies of Others Table 21. Global Peripheral Vasodilator Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Peripheral Vasodilator Drugs Sales Volume by Type (2021-2026) & (k units) Table 23. Global Peripheral Vasodilator Drugs Sales Volume by Type (2027-2032) & (k units) Table 24. Global Peripheral Vasodilator Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Peripheral Vasodilator Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Peripheral Vasodilator Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peripheral Vasodilator Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Peripheral Vasodilator Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Peripheral Vasodilator Drugs Sales Value Share by Type (2021-2026) Table 30. Global Peripheral Vasodilator Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Others Table 34. Global Peripheral Vasodilator Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Peripheral Vasodilator Drugs Sales Volume by Application (2021-2026) & (k units) Table 36. Global Peripheral Vasodilator Drugs Sales Volume by Application (2027-2032) & (k units) Table 37. Global Peripheral Vasodilator Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Peripheral Vasodilator Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Peripheral Vasodilator Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Peripheral Vasodilator Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Peripheral Vasodilator Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Peripheral Vasodilator Drugs Sales Value Share by Application (2021-2026) Table 43. Global Peripheral Vasodilator Drugs Sales Value Share by Application (2027-2032) Table 44. Global Peripheral Vasodilator Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Peripheral Vasodilator Drugs Sales by Region (2021-2026) & (k units) Table 46. Global Peripheral Vasodilator Drugs Sales Market Share by Region (2021-2026) Table 47. Global Peripheral Vasodilator Drugs Sales by Region (2027-2032) & (k units) Table 48. Global Peripheral Vasodilator Drugs Sales Market Share by Region (2027-2032) Table 49. Global Peripheral Vasodilator Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Peripheral Vasodilator Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Peripheral Vasodilator Drugs Sales Value Share by Region (2021-2026) Table 52. Global Peripheral Vasodilator Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Peripheral Vasodilator Drugs Sales Value Share by Region (2027-2032) Table 54. Global Peripheral Vasodilator Drugs Market Average Price (USD/unit) by Region (2021-2026) Table 55. Global Peripheral Vasodilator Drugs Market Average Price (USD/unit) by Region (2027-2032) Table 56. Global Peripheral Vasodilator Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Peripheral Vasodilator Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 59. Global Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2026) Table 60. Global Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 61. Global Peripheral Vasodilator Drugs Sales Market Share by Country (2027-2032) Table 62. Global Peripheral Vasodilator Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Peripheral Vasodilator Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Peripheral Vasodilator Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Peripheral Vasodilator Drugs Sales Value Market Share by Country (2027-2032) Table 66. Endovastec Company Information Table 67. Endovastec Business Overview Table 68. Endovastec Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 69. Endovastec Peripheral Vasodilator Drugs Product Portfolio Table 70. Endovastec Recent Development Table 71. Aotecar Medical-B Company Information Table 72. Aotecar Medical-B Business Overview Table 73. Aotecar Medical-B Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Aotecar Medical-B Peripheral Vasodilator Drugs Product Portfolio Table 75. Aotecar Medical-B Recent Development Table 76. Tibet Cheezheng Tibetan Medicine Co., Ltd Company Information Table 77. Tibet Cheezheng Tibetan Medicine Co., Ltd Business Overview Table 78. Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Product Portfolio Table 80. Tibet Cheezheng Tibetan Medicine Co., Ltd Recent Development Table 81. Teva Pharmaceutical Industries Ltd. Company Information Table 82. Teva Pharmaceutical Industries Ltd. Business Overview Table 83. Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio Table 85. Teva Pharmaceutical Industries Ltd. Recent Development Table 86. Sanofi Company Information Table 87. Sanofi Business Overview Table 88. Sanofi Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Sanofi Peripheral Vasodilator Drugs Product Portfolio Table 90. Sanofi Recent Development Table 91. Novartis AG Company Information Table 92. Novartis AG Business Overview Table 93. Novartis AG Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Novartis AG Peripheral Vasodilator Drugs Product Portfolio Table 95. Novartis AG Recent Development Table 96. Pfizer, Inc. Company Information Table 97. Pfizer, Inc. Business Overview Table 98. Pfizer, Inc. Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Pfizer, Inc. Peripheral Vasodilator Drugs Product Portfolio Table 100. Pfizer, Inc. Recent Development Table 101. GSK plc Company Information Table 102. GSK plc Business Overview Table 103. GSK plc Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. GSK plc Peripheral Vasodilator Drugs Product Portfolio Table 105. GSK plc Recent Development Table 106. Bayer AG Company Information Table 107. Bayer AG Business Overview Table 108. Bayer AG Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Bayer AG Peripheral Vasodilator Drugs Product Portfolio Table 110. Bayer AG Recent Development Table 111. Bat Medical Company Information Table 112. Bat Medical Business Overview Table 113. Bat Medical Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Bat Medical Peripheral Vasodilator Drugs Product Portfolio Table 115. Bat Medical Recent Development Table 116. AstraZeneca Company Information Table 117. AstraZeneca Business Overview Table 118. AstraZeneca Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. AstraZeneca Peripheral Vasodilator Drugs Product Portfolio Table 120. AstraZeneca Recent Development Table 121. Viatris, Inc. Company Information Table 122. Viatris, Inc. Business Overview Table 123. Viatris, Inc. Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Viatris, Inc. Peripheral Vasodilator Drugs Product Portfolio Table 125. Viatris, Inc. Recent Development Table 126. Sun Pharmaceutical Industries Ltd. Company Information Table 127. Sun Pharmaceutical Industries Ltd. Business Overview Table 128. Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio Table 130. Sun Pharmaceutical Industries Ltd. Recent Development Table 131. Merck & Co., Inc. Company Information Table 132. Merck & Co., Inc. Business Overview Table 133. Merck & Co., Inc. Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Merck & Co., Inc. Peripheral Vasodilator Drugs Product Portfolio Table 135. Merck & Co., Inc. Recent Development Table 136. Lupin Company Information Table 137. Lupin Business Overview Table 138. Lupin Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Lupin Peripheral Vasodilator Drugs Product Portfolio Table 140. Lupin Recent Development Table 141. Bristol-Myers Squibb Company Company Information Table 142. Bristol-Myers Squibb Company Business Overview Table 143. Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Product Portfolio Table 145. Bristol-Myers Squibb Company Recent Development Table 146. Boehringer Ingelheim International GmbH Company Information Table 147. Boehringer Ingelheim International GmbH Business Overview Table 148. Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Product Portfolio Table 150. Boehringer Ingelheim International GmbH Recent Development Table 151. Abbott Laboratories Company Information Table 152. Abbott Laboratories Business Overview Table 153. Abbott Laboratories Peripheral Vasodilator Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. Abbott Laboratories Peripheral Vasodilator Drugs Product Portfolio Table 155. Abbott Laboratories Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Peripheral Vasodilator Drugs Distributors List Table 159. Peripheral Vasodilator Drugs Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Peripheral Vasodilator Drugs Product Image Figure 2. Global Peripheral Vasodilator Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripheral Vasodilator Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peripheral Vasodilator Drugs Sales (2021-2032) & (k units) Figure 5. Global Peripheral Vasodilator Drugs Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Peripheral Vasodilator Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alpha-adrenergic Blockers Image Figure 10. Calcium Channel Blockers Image Figure 11. Potassium Channel Activators Image Figure 12. Others Image Figure 13. Global Peripheral Vasodilator Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Peripheral Vasodilator Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Peripheral Vasodilator Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Peripheral Vasodilator Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Peripheral Vasodilator Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Peripheral Vasodilator Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Retail Pharmacies Image Figure 21. Others Image Figure 22. Global Peripheral Vasodilator Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Peripheral Vasodilator Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Peripheral Vasodilator Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Peripheral Vasodilator Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Peripheral Vasodilator Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Peripheral Vasodilator Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Peripheral Vasodilator Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Peripheral Vasodilator Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Peripheral Vasodilator Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Peripheral Vasodilator Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Peripheral Vasodilator Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Peripheral Vasodilator Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Peripheral Vasodilator Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Peripheral Vasodilator Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Peripheral Vasodilator Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Peripheral Vasodilator Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Peripheral Vasodilator Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Peripheral Vasodilator Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Peripheral Vasodilator Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Peripheral Vasodilator Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Peripheral Vasodilator Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Peripheral Vasodilator Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-adrenergic Blockers
  • Calcium Channel Blockers
  • Potassium Channel Activators
  • Others
Applications
  • Hospital
  • Retail Pharmacies
  • Others
Companies covered
  • Endovastec
  • Aotecar Medical-B
  • Tibet Cheezheng Tibetan Medicine Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Pfizer, Inc.
  • GSK plc
  • Bayer AG
  • Bat Medical
  • AstraZeneca
  • Viatris, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Lupin
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peripheral Vasodilator Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Peripheral Vasodilator Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Peripheral Vasodilator Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peripheral Vasodilator Drugs Market Dynamics
  1. 2.1 Peripheral Vasodilator Drugs Industry Trends
  2. 2.2 Peripheral Vasodilator Drugs Industry Drivers
  3. 2.3 Peripheral Vasodilator Drugs Industry Opportunities and Challenges
  4. 2.4 Peripheral Vasodilator Drugs Industry Restraints
3 Peripheral Vasodilator Drugs Market by Company
  1. 3.1 Global Peripheral Vasodilator Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Peripheral Vasodilator Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Peripheral Vasodilator Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Peripheral Vasodilator Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Peripheral Vasodilator Drugs Company Ranking (2024-2026)
  6. 3.6 Global Peripheral Vasodilator Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Peripheral Vasodilator Drugs Company Product Type and Application
  8. 3.8 Global Peripheral Vasodilator Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peripheral Vasodilator Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peripheral Vasodilator Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peripheral Vasodilator Drugs Market by Type
  1. 4.1 Peripheral Vasodilator Drugs Type Introduction
  2. 4.1.1 Alpha-adrenergic Blockers
  3. 4.1.2 Calcium Channel Blockers
  4. 4.1.3 Potassium Channel Activators
  5. 4.1.4 Others
  6. 4.2 Global Peripheral Vasodilator Drugs Sales Volume by Type
  7. 4.2.1 Global Peripheral Vasodilator Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Peripheral Vasodilator Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Peripheral Vasodilator Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Peripheral Vasodilator Drugs Sales Value by Type
  11. 4.3.1 Global Peripheral Vasodilator Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Peripheral Vasodilator Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Peripheral Vasodilator Drugs Sales Value Share by Type (2021-2032)
5 Peripheral Vasodilator Drugs Market by Application
  1. 5.1 Peripheral Vasodilator Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Others
  5. 5.2 Global Peripheral Vasodilator Drugs Sales Volume by Application
  6. 5.2.1 Global Peripheral Vasodilator Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peripheral Vasodilator Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peripheral Vasodilator Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peripheral Vasodilator Drugs Sales Value by Application
  10. 5.3.1 Global Peripheral Vasodilator Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peripheral Vasodilator Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peripheral Vasodilator Drugs Sales Value Share by Application (2021-2032)
6 Peripheral Vasodilator Drugs Regional Sales and Value Analysis
  1. 6.1 Global Peripheral Vasodilator Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peripheral Vasodilator Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Peripheral Vasodilator Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Peripheral Vasodilator Drugs Sales by Region (2027-2032)
  5. 6.3 Global Peripheral Vasodilator Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peripheral Vasodilator Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peripheral Vasodilator Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peripheral Vasodilator Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Peripheral Vasodilator Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peripheral Vasodilator Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Peripheral Vasodilator Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peripheral Vasodilator Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Peripheral Vasodilator Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peripheral Vasodilator Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peripheral Vasodilator Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peripheral Vasodilator Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Peripheral Vasodilator Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peripheral Vasodilator Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peripheral Vasodilator Drugs Sales Value Share by Country, 2025 VS 2032
7 Peripheral Vasodilator Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Peripheral Vasodilator Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peripheral Vasodilator Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Peripheral Vasodilator Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Peripheral Vasodilator Drugs Sales by Country (2027-2032)
  6. 7.4 Global Peripheral Vasodilator Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peripheral Vasodilator Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peripheral Vasodilator Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peripheral Vasodilator Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peripheral Vasodilator Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peripheral Vasodilator Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Endovastec
  2. 8.1.1 Endovastec Company Information
  3. 8.1.2 Endovastec Business Overview
  4. 8.1.3 Endovastec Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Endovastec Peripheral Vasodilator Drugs Product Portfolio
  6. 8.1.5 Endovastec Recent Developments
  7. 8.2 Aotecar Medical-B
  8. 8.2.1 Aotecar Medical-B Company Information
  9. 8.2.2 Aotecar Medical-B Business Overview
  10. 8.2.3 Aotecar Medical-B Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aotecar Medical-B Peripheral Vasodilator Drugs Product Portfolio
  12. 8.2.5 Aotecar Medical-B Recent Developments
  13. 8.3 Tibet Cheezheng Tibetan Medicine Co., Ltd
  14. 8.3.1 Tibet Cheezheng Tibetan Medicine Co., Ltd Company Information
  15. 8.3.2 Tibet Cheezheng Tibetan Medicine Co., Ltd Business Overview
  16. 8.3.3 Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Product Portfolio
  18. 8.3.5 Tibet Cheezheng Tibetan Medicine Co., Ltd Recent Developments
  19. 8.4 Teva Pharmaceutical Industries Ltd.
  20. 8.4.1 Teva Pharmaceutical Industries Ltd. Company Information
  21. 8.4.2 Teva Pharmaceutical Industries Ltd. Business Overview
  22. 8.4.3 Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio
  24. 8.4.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Peripheral Vasodilator Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Novartis AG
  32. 8.6.1 Novartis AG Company Information
  33. 8.6.2 Novartis AG Business Overview
  34. 8.6.3 Novartis AG Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis AG Peripheral Vasodilator Drugs Product Portfolio
  36. 8.6.5 Novartis AG Recent Developments
  37. 8.7 Pfizer, Inc.
  38. 8.7.1 Pfizer, Inc. Company Information
  39. 8.7.2 Pfizer, Inc. Business Overview
  40. 8.7.3 Pfizer, Inc. Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer, Inc. Peripheral Vasodilator Drugs Product Portfolio
  42. 8.7.5 Pfizer, Inc. Recent Developments
  43. 8.8 GSK plc
  44. 8.8.1 GSK plc Company Information
  45. 8.8.2 GSK plc Business Overview
  46. 8.8.3 GSK plc Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK plc Peripheral Vasodilator Drugs Product Portfolio
  48. 8.8.5 GSK plc Recent Developments
  49. 8.9 Bayer AG
  50. 8.9.1 Bayer AG Company Information
  51. 8.9.2 Bayer AG Business Overview
  52. 8.9.3 Bayer AG Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bayer AG Peripheral Vasodilator Drugs Product Portfolio
  54. 8.9.5 Bayer AG Recent Developments
  55. 8.10 Bat Medical
  56. 8.10.1 Bat Medical Company Information
  57. 8.10.2 Bat Medical Business Overview
  58. 8.10.3 Bat Medical Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bat Medical Peripheral Vasodilator Drugs Product Portfolio
  60. 8.10.5 Bat Medical Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Peripheral Vasodilator Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Viatris, Inc.
  68. 8.12.1 Viatris, Inc. Company Information
  69. 8.12.2 Viatris, Inc. Business Overview
  70. 8.12.3 Viatris, Inc. Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Viatris, Inc. Peripheral Vasodilator Drugs Product Portfolio
  72. 8.12.5 Viatris, Inc. Recent Developments
  73. 8.13 Sun Pharmaceutical Industries Ltd.
  74. 8.13.1 Sun Pharmaceutical Industries Ltd. Company Information
  75. 8.13.2 Sun Pharmaceutical Industries Ltd. Business Overview
  76. 8.13.3 Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio
  78. 8.13.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  79. 8.14 Merck & Co., Inc.
  80. 8.14.1 Merck & Co., Inc. Company Information
  81. 8.14.2 Merck & Co., Inc. Business Overview
  82. 8.14.3 Merck & Co., Inc. Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck & Co., Inc. Peripheral Vasodilator Drugs Product Portfolio
  84. 8.14.5 Merck & Co., Inc. Recent Developments
  85. 8.15 Lupin
  86. 8.15.1 Lupin Company Information
  87. 8.15.2 Lupin Business Overview
  88. 8.15.3 Lupin Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Lupin Peripheral Vasodilator Drugs Product Portfolio
  90. 8.15.5 Lupin Recent Developments
  91. 8.16 Bristol-Myers Squibb Company
  92. 8.16.1 Bristol-Myers Squibb Company Company Information
  93. 8.16.2 Bristol-Myers Squibb Company Business Overview
  94. 8.16.3 Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Product Portfolio
  96. 8.16.5 Bristol-Myers Squibb Company Recent Developments
  97. 8.17 Boehringer Ingelheim International GmbH
  98. 8.17.1 Boehringer Ingelheim International GmbH Company Information
  99. 8.17.2 Boehringer Ingelheim International GmbH Business Overview
  100. 8.17.3 Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Product Portfolio
  102. 8.17.5 Boehringer Ingelheim International GmbH Recent Developments
  103. 8.18 Abbott Laboratories
  104. 8.18.1 Abbott Laboratories Company Information
  105. 8.18.2 Abbott Laboratories Business Overview
  106. 8.18.3 Abbott Laboratories Peripheral Vasodilator Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Abbott Laboratories Peripheral Vasodilator Drugs Product Portfolio
  108. 8.18.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peripheral Vasodilator Drugs Value Chain Analysis
  2. 9.1.1 Peripheral Vasodilator Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peripheral Vasodilator Drugs Sales Mode & Process
  6. 9.2 Peripheral Vasodilator Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peripheral Vasodilator Drugs Distributors
  9. 9.2.3 Peripheral Vasodilator Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst